Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

Molecular and Cellular Biology

Volumn 24, Issue 12, 2004, Pages 5434-5446

  Ueki, Kohjiro ^a,c   Kondo, Tatsuya ^a   Kahn, C Ronald ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPOPOLYSACCHARIDE; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; GLYCOGEN SYNTHESIS; INSULIN RESISTANCE; LIVER; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELLS, CULTURED; DNA, COMPLEMENTARY; ENDOTOXEMIA; FEMALE; GENE EXPRESSION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; PHOSPHORYLATION; REPRESSOR PROTEINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS; TYROSINE; UP-REGULATION;

ADENOVIRIDAE; ANIMALIA;

EID: 2942628012     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.12.5434-5446.2004     Document Type: Article

References (58)

1. Aguirre, V., T. Uchida, L. Yenush, R. Davis, and M. F. White. 2000. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275:9047-9054.
2. Aguirre, V., E. D. Werner, J. Giraud, Y. H. Lee, S. E. Shoelson, and M. F. White. 2002. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277:1531-1537.
3. Barkai, U., A. Prigent-Tessier, C. Tessier, G. B. Gibori, and G. Gibori. 2000. Involvement of SOCS-1, the suppressor of cytokine signaling, in the prevention of prolactin-responsive gene expression in decidual cells. Mol. Endocrinol. 14:554-563.
4. Bruning, J. C., J. Winnay, S. Bonner-Weir, S. I. Taylor, D. Accili, and C. R. Kahn. 1997. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88:561-572.
5. Butler, M., R. A. McKay, I. J. Popoff, W. A. Gaarde, D. Witchell, S. F. Murray, N. M. Dean, S. Bhanot, and B. P. Monia. 2002. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51:1028-1034.
6. Chang, C. K., S. F. Moskal, Jr., K. S. Srivenugopal, and W. Schumer. 1993. Altered levels of mRNA encoding enzymes of hepatic glucose metabolism in septic rats. Circ. Shock 41:35-39.
7. Cho, H., J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw III, K. H. Kaestner, M. S. Bartolomei, G. I. Shulman, and M. J. Birnbaum. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731.
8. Desepulveda, P., S. Ilangumaran, and R. Rottapel. 2000. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J. Biol. Chem. 275:14005-14008.
9. Dey, B. R., S. L. Spence, P. Nissley, and R. W. Furlanetto. 1998. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273:24095-24101.
10. Eck, M. J., S. Dhe-Paganon, T. Trub, R. T. Nolte, and S. E. Shoelson. 1996. Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 85:695-705.
11. Emanuelli, B., P. Peraldi, C. Filloux, D. Sawka-Verhelle, D. Hilton, and E. Van Obberghen. 2000. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275:15985-15991.
12. Endo, T. A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, T. Miyazaki, N. Leonor, T. Taniguchi, T. Fujita, Y. Kanakura, S. Komiya, and A. Yoshimura. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924.
13. Engelman, J. A., A. H. Berg, R. Y. Lewis, M. P. Lisanti, and P. E. Scherer. 2000. Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Mol. Endocrinol. 14:1557-1569.
14. Feinstein, R., H. Kanety, M. Z. Papa, B. Lunenfeld, and A. Karasik. 1993. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 268:26055-26058.
15. Fernandez-Real, J. M., M. Broch, J. Vendrell, C. Gutierrez, R. Casamitjana, M. Pugeat, C. Richart, and W. Ricart. 2000. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520.
16. Guha, M., and N. Mackman. 2001. LPS induction of gene expression in human monocytes. Cell Signal. 13:85-94.
17. He, W., A. Craparo, Y. Zhu, T. J. O'Neill, L. M. Wang, J. H. Pierce, and T. A. Gustafson. 1996. Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J. Biol. Chem. 271:11641-11645.
18. Hirashima, Y., K. Tsuruzoe, S. Kodama, M. Igata, T. Toyonaga, K. Ueki, C. R. Kahn, and E. Araki. 2003. Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. J. Endocrinol. 179:253-266.
19. Hotamisligil, G. S., P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668.
20. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91.
21. Kahn, C. R., and J. Roth. 1975. Cell membrane receptors for polypeptide hormones. Application to the study of disease states in mice, and men. Am. J. Clin. Pathol. 63:656-667.
22. Kamizono, S., T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, M. Minoguchi, K. Hattori, S. Hatakeyama, M. Yada, S. Morita, T. Kitamura, H. Kato, K. Nakayama, and A. Yoshimura. 2001. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276:12530-12538.
23. Kamura, T., S. Sato, D. Haque, L. Liu, W. G. Kaelin, Jr., R. C. Conaway, and J. W. Conaway. 1998. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-3881.
24. Karasik, A., P. L. Rothenberg, K. Yamada, M. F. White, and C. F. Kahn. 1990. Increased protein kinase C activity is linked to reduced insulin receptor autophosphorylation in liver of starved rats. J. Biol. Chem. 265:10226-10231.
25. Kawazoe, Y., T. Naka, M. Fujimoto, H. Kohzaki, Y. Morita, M. Narazaki, K. Okumura, H. Saitoh, R. Nakagawa, Y. Uchiyama, S. Akira, and T. Kishimoto. 2001. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193:263-269.
26. Ling, P. R., B. R. Bistrian, B. Mendez, and N. W. Istfan. 1994. Effects of systemic infusions of endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and peripheral tissue glucose uptake. Metabolism 43:279-284.
27. Marine, J. C., C. McKay, D. Wang, D. J. Topham, E. Parganas, H. Nakajima, H. Pendeville, H. Yasukawa, A. Sasaki, A. Yoshimura, and J. N. Ihle. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98:617-627.
28. Marine, J. C., D. J. Topham, C. McKay, D. Wang, E. Parganas, D. Stravopodis, A. Yoshimura, and J. N. Ihle. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98:609-616.
29. Martich, G. D., A. J. Boujoukos, and A. F. Suffredini. 1993. Response of man to endotoxin. Immunobiology 187:403-416.
30. Michael, M. D., R. N. Kulkarni, C. Postic, S. F. Previs, G. I. Shulman, M. A. Magnuson, and C. R. Kahn. 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6:87-97.
31. Mooney, R. A., J. Senn, S. Cameron, N. Inamdar, L. M. Boivin, Y. Shang, and R. W. Furlanetto. 2001. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J. Biol. Chem. 276:25889-25893.
32. Naka, T., T. Matsumoto, M. Narazaki, M. Fujimoto, Y. Morita, Y. Ohsawa, H. Saito, T. Nagasawa, Y. Uchiyama, and T. Kishimoto. 1998. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. USA 95:15577-15582.
33. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, S. Akira, and T. Kishimoto. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-929.
34. Narazaki, M., M. Fujimoto, T. Matsumoto, Y. Morita, H. Saito, T. Kajita, K. Yoshizaki, T. Naka, and T. Kishimoto. 1998. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. USA 95:13130-13134.
35. Peraldi, P., C. Filloux, B. Emanuelli, D. J. Hilton, and E. Van Obberghen. 2001. Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J. Biol. Chem. 276:24614-24620.
36. Peraldi, P., G. S. Hotamisligil, W. A. Buurman, M. F. White, and B. M. Spiegelman. 1996. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271:13018-13022.
37. Peraldi, P., and B. Spiegelman. 1998. TNF-alpha and insulin resistance: summary and future prospects. Mol. Cell. Biochem. 182:169-175.
38. Pradhan, A. D., J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334.
39. Rui, L., M. Yuan, D. Frantz, S. Shoelson, and M. F. White. 2002. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277:42394-42398.
40. Saito, H., Y. Morita, M. Fujimoto, M. Narazaki, T. Naka, and T. Kishimoto. 2000. IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma. J. Immunol. 164:5833-5843.
41. Sasaki, A., H. Yasukawa, T. Shouda, T. Kitamura, I. Dikic, and A. Yoshimura. 2000. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem. 275:29338-29347.
42. Sawka-Verhelle, D., S. Tartare-Deckert, M. F. White, and E. Van Obberghen. 1996. Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. J. Biol. Chem. 271:5980-5983.
43. Shimomura, I., M. Matsuda, R. E. Hammer, Y. Bashmakov, M. S. Brown, and J. L. Goldstein. 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell. 6:77-86.
44. Starr, R., D. Metcalf, A. G. Elefanty, M. Brysha, T. A. Willson, N. A. Nicola, D. J. Hilton, and W. S. Alexander. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95:14395-14399.
45. Starr, R., T. A. Willson, E. M. Viney, L. J. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921.
46. Suffredini, A. F., G. Fantuzzi, R. Badolato, J. J. Oppenheim, and N. P. O'Grady. 1999. New insights into the biology of the acute phase response. J. Clin. Immunol. 19:203-214.
47. Sugita, H., M. Kaneki, E. Tokunaga, M. Sugita, C. Koike, S. Yasuhara, R. G. Tompkins, and J. A. Martyn. 2002. Inducible nitric oxide synthase plays a role in LPS-induced hyperglycemia and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 282:E386-E394.
48. Takayama, S., M. F. White, and C. R. Kahn. 1988. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J. Biol. Chem. 263:3440-3447.
49. Ueki, K., R. Yamamoto-Honda, Y. Kaburagi, T. Yamauchi, K. Tobe, B. M. Burgering, P. J. Coffer, I. Komuro, Y. Akanuma, Y. Yazaki, and T. Kadowaki. 1998. Potential role of protein kinase B in insulin-induced glucose transport, glycogen synthesis, and protein synthesis. J. Biol. Chem. 273:5315-5322.
50. Ueki, K., T. Yamauchi, H. Tamemoto, K. Tobe, R. Yamamoto-Honda, Y. Kaburagi, Y. Akanuma, Y. Yazaki, S. Aizawa, R. Nagai, and T. Kadowaki. 2000. Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J. Clin. Investig. 105:1437-1445.
51. Uysal, K. T., S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614.
52. Virkamaki, A., K. Ueki, and C. R. Kahn. 1999. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Investig. 103:931-943.
53. Virkamaki, A., and H. Yki-Jarvinen. 1994. Mechanisms of insulin resistance during acute endotoxemia. Endocrinology 134:2072-2078.
54. White, M. F., J. N. Livingston, J. M. Backer, V. Lauris, T. J. Dull, A. Ullrich, and C. R. Kahn. 1988. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 54:641-649.
55. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imatzumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-1320.
56. Yasukawa, H., A. Sasaki, and A. Yoshimura. 2000. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:143-164.
57. Yuan, M., N. Konstantopoulos, J. Lee, L. Hansen, Z. W. Li, M. Karin, and S. E. Shoelson. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293:1673-1677.
58. Zong, C. S., J. Chan, D. E. Levy, C. Horvath, H. B. Sadowski, and L. H. Wang. 2000. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 275:15099-15105.